Endexx Corporation is only halfway through its 2023 fiscal first quarter, and yet has already surpassed its best yearly revenue figure by more than 500%, the company said.
The plant-based health and skincare product company attributed the record achievement to a combination of HYLA vape international purchase orders from Italy, Dubai and elsewhere. Endexx acquired HYLA US Holdco, which produces and distributes organic, guarana-based, all-natural, zero-nicotine vape products, earlier this year.
Additionally, the company’s CBD pain products and men’s skincare line began sales in 13 countries on Amazon. In the US, the two products are available in four of the country’s top eight retailers: Amazon, along with Walgreens, Target and CVS stores.
READ: Endexx receives US$3.8M order for its HYLA vape product from customers in Italy
“Our acquisition of HYLA has already exceeded our expectations, and the revenue has more than paid for our cash outlay to acquire the company,” CEO Todd Davis said in a statement.
“We believe that the powerful distribution network that HYLA brought to the table, combined with our increasing presence in U.S. retail, will continue to reap benefits beyond this quarter and regularly create new record-setting opportunities. We continue to expand our market presence for all categories, and expect to provide new and exciting updates across our three product lines over the coming quarters.”
HYLA has been in demand for both its natural ingredients, including guarana and L-dopa, and feedback on the superior experience and assortment, according to the company.
Through its operating division CBD Unlimited, Endexx develops and distributes all-natural CBD products derived from cannabis sativa plants containing less than 0.1% THC. Its products include oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel